nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Carboplatin—testicular cancer	0.106	0.131	CbGbCtD
Canagliflozin—ABCC2—Vinblastine—testicular cancer	0.0983	0.122	CbGbCtD
Canagliflozin—ABCC2—Cisplatin—testicular cancer	0.0902	0.112	CbGbCtD
Canagliflozin—ABCC2—Etoposide—testicular cancer	0.0886	0.11	CbGbCtD
Canagliflozin—ABCC2—Doxorubicin—testicular cancer	0.0604	0.0753	CbGbCtD
Canagliflozin—ABCC2—Methotrexate—testicular cancer	0.0585	0.0729	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—testicular cancer	0.0512	0.0637	CbGbCtD
Canagliflozin—ALB—Methotrexate—testicular cancer	0.0365	0.0454	CbGbCtD
Canagliflozin—CYP3A4—Ifosfamide—testicular cancer	0.0362	0.0451	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—testicular cancer	0.0321	0.0399	CbGbCtD
Canagliflozin—ABCB1—Cisplatin—testicular cancer	0.0294	0.0366	CbGbCtD
Canagliflozin—ABCB1—Etoposide—testicular cancer	0.0289	0.036	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—testicular cancer	0.0197	0.0245	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—testicular cancer	0.0192	0.0239	CbGbCtD
Canagliflozin—ABCB1—Methotrexate—testicular cancer	0.0191	0.0238	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—testicular cancer	0.0173	0.0216	CbGbCtD
Canagliflozin—CYP3A4—Doxorubicin—testicular cancer	0.0118	0.0147	CbGbCtD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00549	0.15	CbGpPWpGaD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00549	0.15	CbGpPWpGaD
Canagliflozin—SLC5A1—NRF2 pathway—SLC2A6—testicular cancer	0.00396	0.108	CbGpPWpGaD
Canagliflozin—SLC5A2—NRF2 pathway—SLC2A6—testicular cancer	0.00396	0.108	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00249	0.0681	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00249	0.0681	CbGpPWpGaD
Canagliflozin—UGT2B4—Phase II conjugation—HPGDS—testicular cancer	0.00166	0.0454	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00127	0.0346	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00127	0.0346	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—SLC2A6—testicular cancer	0.00113	0.0309	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.0011	0.0301	CbGpPWpGaD
Canagliflozin—Rash maculo-papular—Etoposide—testicular cancer	0.00105	0.00652	CcSEcCtD
Canagliflozin—Polyuria—Cisplatin—testicular cancer	0.00104	0.00647	CcSEcCtD
Canagliflozin—Blood creatinine increased—Ifosfamide—testicular cancer	0.000992	0.00617	CcSEcCtD
Canagliflozin—Renal failure acute—Cisplatin—testicular cancer	0.000989	0.00615	CcSEcCtD
Canagliflozin—UGT2B4—Biological oxidations—HPGDS—testicular cancer	0.000973	0.0266	CbGpPWpGaD
Canagliflozin—Serum creatinine increased—Doxorubicin—testicular cancer	0.000971	0.00605	CcSEcCtD
Canagliflozin—Breast disorder—Ifosfamide—testicular cancer	0.000957	0.00595	CcSEcCtD
Canagliflozin—Pancreatitis—Ifosfamide—testicular cancer	0.000897	0.00558	CcSEcCtD
Canagliflozin—Angioedema—Chlorambucil—testicular cancer	0.000881	0.00548	CcSEcCtD
Canagliflozin—Blood creatinine increased—Cisplatin—testicular cancer	0.000855	0.00532	CcSEcCtD
Canagliflozin—Dehydration—Cisplatin—testicular cancer	0.000849	0.00528	CcSEcCtD
Canagliflozin—Pollakiuria—Ifosfamide—testicular cancer	0.000845	0.00526	CcSEcCtD
Canagliflozin—Rash erythematous—Epirubicin—testicular cancer	0.000843	0.00525	CcSEcCtD
Canagliflozin—Convulsion—Chlorambucil—testicular cancer	0.000835	0.0052	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Cisplatin—testicular cancer	0.000834	0.00519	CcSEcCtD
Canagliflozin—Breast disorder—Cisplatin—testicular cancer	0.000825	0.00513	CcSEcCtD
Canagliflozin—Rash pustular—Epirubicin—testicular cancer	0.00081	0.00504	CcSEcCtD
Canagliflozin—Infection—Chlorambucil—testicular cancer	0.000782	0.00486	CcSEcCtD
Canagliflozin—Rash erythematous—Doxorubicin—testicular cancer	0.00078	0.00486	CcSEcCtD
Canagliflozin—Pancreatitis—Cisplatin—testicular cancer	0.000774	0.00481	CcSEcCtD
Canagliflozin—Convulsion—Vinblastine—testicular cancer	0.000765	0.00476	CcSEcCtD
Canagliflozin—Rash pustular—Doxorubicin—testicular cancer	0.000749	0.00466	CcSEcCtD
Canagliflozin—Erythema—Bleomycin—testicular cancer	0.000746	0.00464	CcSEcCtD
Canagliflozin—Urinary tract disorder—Ifosfamide—testicular cancer	0.000723	0.0045	CcSEcCtD
Canagliflozin—Urethral disorder—Ifosfamide—testicular cancer	0.000718	0.00447	CcSEcCtD
Canagliflozin—Nocturia—Epirubicin—testicular cancer	0.000696	0.00433	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—testicular cancer	0.000696	0.00433	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.000679	0.00423	CcSEcCtD
Canagliflozin—Fatigue—Chlorambucil—testicular cancer	0.000678	0.00422	CcSEcCtD
Canagliflozin—Cystitis noninfective—Methotrexate—testicular cancer	0.000674	0.00419	CcSEcCtD
Canagliflozin—Cystitis—Methotrexate—testicular cancer	0.000666	0.00415	CcSEcCtD
Canagliflozin—Angiopathy—Ifosfamide—testicular cancer	0.000665	0.00414	CcSEcCtD
Canagliflozin—Vaginal infection—Methotrexate—testicular cancer	0.000651	0.00405	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—testicular cancer	0.000644	0.00401	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000643	0.004	CcSEcCtD
Canagliflozin—Erythema—Ifosfamide—testicular cancer	0.000638	0.00397	CcSEcCtD
Canagliflozin—Malnutrition—Ifosfamide—testicular cancer	0.000638	0.00397	CcSEcCtD
Canagliflozin—Hyperkalaemia—Epirubicin—testicular cancer	0.000634	0.00395	CcSEcCtD
Canagliflozin—Cystitis noninfective—Epirubicin—testicular cancer	0.000631	0.00393	CcSEcCtD
Canagliflozin—Urticaria—Chlorambucil—testicular cancer	0.000625	0.00389	CcSEcCtD
Canagliflozin—Urine output increased—Methotrexate—testicular cancer	0.000624	0.00388	CcSEcCtD
Canagliflozin—Bladder pain—Methotrexate—testicular cancer	0.000624	0.00388	CcSEcCtD
Canagliflozin—Urinary tract disorder—Cisplatin—testicular cancer	0.000624	0.00388	CcSEcCtD
Canagliflozin—Cystitis—Epirubicin—testicular cancer	0.000624	0.00388	CcSEcCtD
Canagliflozin—Abdominal pain—Chlorambucil—testicular cancer	0.000622	0.00387	CcSEcCtD
Canagliflozin—Urethral disorder—Cisplatin—testicular cancer	0.000619	0.00385	CcSEcCtD
Canagliflozin—Constipation—Vinblastine—testicular cancer	0.000617	0.00384	CcSEcCtD
Canagliflozin—UGT1A9—Phase II conjugation—HPGDS—testicular cancer	0.000615	0.0168	CbGpPWpGaD
Canagliflozin—Vaginal infection—Epirubicin—testicular cancer	0.00061	0.00379	CcSEcCtD
Canagliflozin—Blood urea increased—Epirubicin—testicular cancer	0.00061	0.00379	CcSEcCtD
Canagliflozin—Infection—Bleomycin—testicular cancer	0.000605	0.00376	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinblastine—testicular cancer	0.00059	0.00367	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—testicular cancer	0.000587	0.00365	CcSEcCtD
Canagliflozin—Rash maculo-papular—Epirubicin—testicular cancer	0.000587	0.00365	CcSEcCtD
Canagliflozin—Bladder pain—Epirubicin—testicular cancer	0.000584	0.00363	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—testicular cancer	0.000584	0.00363	CcSEcCtD
Canagliflozin—Angioedema—Ifosfamide—testicular cancer	0.000583	0.00363	CcSEcCtD
Canagliflozin—Hypersensitivity—Chlorambucil—testicular cancer	0.00058	0.00361	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—testicular cancer	0.000577	0.00359	CcSEcCtD
Canagliflozin—Diabetes mellitus—Methotrexate—testicular cancer	0.000576	0.00358	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—testicular cancer	0.000571	0.00356	CcSEcCtD
Canagliflozin—Photosensitivity—Methotrexate—testicular cancer	0.00057	0.00355	CcSEcCtD
Canagliflozin—Polyuria—Methotrexate—testicular cancer	0.00057	0.00355	CcSEcCtD
Canagliflozin—Abdominal pain—Vinblastine—testicular cancer	0.00057	0.00355	CcSEcCtD
Canagliflozin—Hypotension—Bleomycin—testicular cancer	0.000569	0.00354	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—testicular cancer	0.000567	0.00353	CcSEcCtD
Canagliflozin—Asthenia—Chlorambucil—testicular cancer	0.000564	0.00351	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—testicular cancer	0.000564	0.00351	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—testicular cancer	0.000564	0.00351	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—testicular cancer	0.000564	0.00351	CcSEcCtD
Canagliflozin—Pruritus—Chlorambucil—testicular cancer	0.000557	0.00346	CcSEcCtD
Canagliflozin—Convulsion—Ifosfamide—testicular cancer	0.000552	0.00344	CcSEcCtD
Canagliflozin—Malnutrition—Cisplatin—testicular cancer	0.00055	0.00342	CcSEcCtD
Canagliflozin—Erythema—Cisplatin—testicular cancer	0.00055	0.00342	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—testicular cancer	0.000543	0.00338	CcSEcCtD
Canagliflozin—Renal failure acute—Methotrexate—testicular cancer	0.000543	0.00338	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—testicular cancer	0.00054	0.00336	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.000539	0.00336	CcSEcCtD
Canagliflozin—Diabetes mellitus—Epirubicin—testicular cancer	0.000539	0.00335	CcSEcCtD
Canagliflozin—Photosensitivity—Epirubicin—testicular cancer	0.000534	0.00332	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinblastine—testicular cancer	0.000531	0.00331	CcSEcCtD
Canagliflozin—Angiopathy—Etoposide—testicular cancer	0.000525	0.00327	CcSEcCtD
Canagliflozin—Asthenia—Vinblastine—testicular cancer	0.000517	0.00322	CcSEcCtD
Canagliflozin—Infection—Ifosfamide—testicular cancer	0.000517	0.00322	CcSEcCtD
Canagliflozin—Nervous system disorder—Ifosfamide—testicular cancer	0.00051	0.00318	CcSEcCtD
Canagliflozin—Renal failure acute—Epirubicin—testicular cancer	0.000508	0.00316	CcSEcCtD
Canagliflozin—Skin disorder—Ifosfamide—testicular cancer	0.000505	0.00315	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—testicular cancer	0.000499	0.0031	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—testicular cancer	0.000494	0.00307	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—testicular cancer	0.00049	0.00305	CcSEcCtD
Canagliflozin—Hypotension—Ifosfamide—testicular cancer	0.000486	0.00303	CcSEcCtD
Canagliflozin—Urticaria—Bleomycin—testicular cancer	0.000484	0.00301	CcSEcCtD
Canagliflozin—Hypoglycaemia—Epirubicin—testicular cancer	0.00048	0.00299	CcSEcCtD
Canagliflozin—Dizziness—Vinblastine—testicular cancer	0.000477	0.00297	CcSEcCtD
Canagliflozin—Convulsion—Cisplatin—testicular cancer	0.000476	0.00296	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—testicular cancer	0.00047	0.00292	CcSEcCtD
Canagliflozin—Nausea—Chlorambucil—testicular cancer	0.000467	0.00291	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000465	0.00289	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000464	0.00289	CcSEcCtD
Canagliflozin—Breast disorder—Methotrexate—testicular cancer	0.000453	0.00282	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000449	0.0028	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—testicular cancer	0.000449	0.00279	CcSEcCtD
Canagliflozin—Fatigue—Ifosfamide—testicular cancer	0.000449	0.00279	CcSEcCtD
Canagliflozin—Hypersensitivity—Bleomycin—testicular cancer	0.000449	0.00279	CcSEcCtD
Canagliflozin—Infection—Cisplatin—testicular cancer	0.000446	0.00277	CcSEcCtD
Canagliflozin—Constipation—Ifosfamide—testicular cancer	0.000445	0.00277	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—testicular cancer	0.000444	0.00277	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—testicular cancer	0.000443	0.00275	CcSEcCtD
Canagliflozin—Nervous system disorder—Cisplatin—testicular cancer	0.00044	0.00274	CcSEcCtD
Canagliflozin—Blood creatinine increased—Epirubicin—testicular cancer	0.000439	0.00273	CcSEcCtD
Canagliflozin—Asthenia—Bleomycin—testicular cancer	0.000437	0.00272	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—testicular cancer	0.000436	0.00272	CcSEcCtD
Canagliflozin—Dehydration—Epirubicin—testicular cancer	0.000436	0.00271	CcSEcCtD
Canagliflozin—Skin disorder—Cisplatin—testicular cancer	0.000436	0.00271	CcSEcCtD
Canagliflozin—Pruritus—Bleomycin—testicular cancer	0.000431	0.00268	CcSEcCtD
Canagliflozin—Nausea—Vinblastine—testicular cancer	0.000428	0.00267	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Epirubicin—testicular cancer	0.000428	0.00266	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.000426	0.00265	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000426	0.00265	CcSEcCtD
Canagliflozin—Pancreatitis—Methotrexate—testicular cancer	0.000424	0.00264	CcSEcCtD
Canagliflozin—Breast disorder—Epirubicin—testicular cancer	0.000424	0.00264	CcSEcCtD
Canagliflozin—Hypotension—Cisplatin—testicular cancer	0.000419	0.00261	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—testicular cancer	0.000418	0.0026	CcSEcCtD
Canagliflozin—Urticaria—Ifosfamide—testicular cancer	0.000413	0.00257	CcSEcCtD
Canagliflozin—Abdominal pain—Ifosfamide—testicular cancer	0.000411	0.00256	CcSEcCtD
Canagliflozin—Infection—Etoposide—testicular cancer	0.000408	0.00254	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—testicular cancer	0.000407	0.00254	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—testicular cancer	0.000406	0.00253	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—testicular cancer	0.000403	0.00251	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—testicular cancer	0.000399	0.00248	CcSEcCtD
Canagliflozin—Pancreatitis—Epirubicin—testicular cancer	0.000397	0.00247	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—testicular cancer	0.000396	0.00247	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Methotrexate—testicular cancer	0.000395	0.00246	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—testicular cancer	0.000392	0.00244	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000387	0.00241	CcSEcCtD
Canagliflozin—Hypotension—Etoposide—testicular cancer	0.000384	0.00239	CcSEcCtD
Canagliflozin—Rash—Bleomycin—testicular cancer	0.000384	0.00239	CcSEcCtD
Canagliflozin—Dermatitis—Bleomycin—testicular cancer	0.000384	0.00239	CcSEcCtD
Canagliflozin—Hypersensitivity—Ifosfamide—testicular cancer	0.000383	0.00239	CcSEcCtD
Canagliflozin—Pollakiuria—Epirubicin—testicular cancer	0.000374	0.00233	CcSEcCtD
Canagliflozin—Asthenia—Ifosfamide—testicular cancer	0.000373	0.00232	CcSEcCtD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000373	0.0102	CbGpPWpGaD
Canagliflozin—Photosensitivity reaction—Epirubicin—testicular cancer	0.00037	0.0023	CcSEcCtD
Canagliflozin—Pruritus—Ifosfamide—testicular cancer	0.000368	0.00229	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—testicular cancer	0.000368	0.00229	CcSEcCtD
Canagliflozin—Nausea—Bleomycin—testicular cancer	0.000362	0.00225	CcSEcCtD
Canagliflozin—UGT1A9—Biological oxidations—HPGDS—testicular cancer	0.00036	0.00983	CbGpPWpGaD
Canagliflozin—Rash—Dactinomycin—testicular cancer	0.000358	0.00223	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Etoposide—testicular cancer	0.000355	0.00221	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—testicular cancer	0.000354	0.00221	CcSEcCtD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000353	0.00965	CbGpPWpGaD
Canagliflozin—Constipation—Etoposide—testicular cancer	0.000351	0.00219	CcSEcCtD
Canagliflozin—Urinary tract infection—Epirubicin—testicular cancer	0.000351	0.00219	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—testicular cancer	0.000346	0.00216	CcSEcCtD
Canagliflozin—Dizziness—Ifosfamide—testicular cancer	0.000344	0.00214	CcSEcCtD
Canagliflozin—Urinary tract disorder—Methotrexate—testicular cancer	0.000342	0.00213	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000342	0.00213	CcSEcCtD
Canagliflozin—Urethral disorder—Methotrexate—testicular cancer	0.00034	0.00211	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—testicular cancer	0.000337	0.0021	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—testicular cancer	0.000336	0.00209	CcSEcCtD
Canagliflozin—Hypersensitivity—Cisplatin—testicular cancer	0.000331	0.00206	CcSEcCtD
Canagliflozin—Rash—Ifosfamide—testicular cancer	0.000328	0.00204	CcSEcCtD
Canagliflozin—Dermatitis—Ifosfamide—testicular cancer	0.000328	0.00204	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—testicular cancer	0.000327	0.00203	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—testicular cancer	0.000325	0.00202	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—testicular cancer	0.000325	0.00202	CcSEcCtD
Canagliflozin—Asthenia—Cisplatin—testicular cancer	0.000322	0.002	CcSEcCtD
Canagliflozin—Urinary tract disorder—Epirubicin—testicular cancer	0.00032	0.00199	CcSEcCtD
Canagliflozin—Urethral disorder—Epirubicin—testicular cancer	0.000318	0.00198	CcSEcCtD
Canagliflozin—Angiopathy—Methotrexate—testicular cancer	0.000314	0.00196	CcSEcCtD
Canagliflozin—Nausea—Ifosfamide—testicular cancer	0.000309	0.00192	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—testicular cancer	0.000303	0.00188	CcSEcCtD
Canagliflozin—Malnutrition—Methotrexate—testicular cancer	0.000302	0.00188	CcSEcCtD
Canagliflozin—Erythema—Methotrexate—testicular cancer	0.000302	0.00188	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—testicular cancer	0.000296	0.00184	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—testicular cancer	0.000295	0.00184	CcSEcCtD
Canagliflozin—Angiopathy—Epirubicin—testicular cancer	0.000294	0.00183	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—testicular cancer	0.000294	0.00183	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—testicular cancer	0.000291	0.00181	CcSEcCtD
Canagliflozin—Rash—Cisplatin—testicular cancer	0.000283	0.00176	CcSEcCtD
Canagliflozin—Dermatitis—Cisplatin—testicular cancer	0.000283	0.00176	CcSEcCtD
Canagliflozin—Erythema—Epirubicin—testicular cancer	0.000282	0.00176	CcSEcCtD
Canagliflozin—Malnutrition—Epirubicin—testicular cancer	0.000282	0.00176	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—testicular cancer	0.000272	0.00169	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—testicular cancer	0.000272	0.00169	CcSEcCtD
Canagliflozin—Nausea—Cisplatin—testicular cancer	0.000266	0.00166	CcSEcCtD
Canagliflozin—Convulsion—Methotrexate—testicular cancer	0.000261	0.00163	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—testicular cancer	0.000261	0.00163	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—testicular cancer	0.000261	0.00163	CcSEcCtD
Canagliflozin—Rash—Etoposide—testicular cancer	0.000259	0.00161	CcSEcCtD
Canagliflozin—Dermatitis—Etoposide—testicular cancer	0.000259	0.00161	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000255	0.00159	CcSEcCtD
Canagliflozin—Syncope—Epirubicin—testicular cancer	0.000253	0.00158	CcSEcCtD
Canagliflozin—Loss of consciousness—Epirubicin—testicular cancer	0.000248	0.00154	CcSEcCtD
Canagliflozin—Convulsion—Epirubicin—testicular cancer	0.000245	0.00152	CcSEcCtD
Canagliflozin—Infection—Methotrexate—testicular cancer	0.000245	0.00152	CcSEcCtD
Canagliflozin—Nausea—Etoposide—testicular cancer	0.000244	0.00152	CcSEcCtD
Canagliflozin—Nervous system disorder—Methotrexate—testicular cancer	0.000241	0.0015	CcSEcCtD
Canagliflozin—Skin disorder—Methotrexate—testicular cancer	0.000239	0.00149	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000239	0.00149	CcSEcCtD
Canagliflozin—Dry mouth—Epirubicin—testicular cancer	0.000235	0.00146	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—testicular cancer	0.000234	0.00146	CcSEcCtD
Canagliflozin—Hypotension—Methotrexate—testicular cancer	0.00023	0.00143	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—testicular cancer	0.00023	0.00143	CcSEcCtD
Canagliflozin—Infection—Epirubicin—testicular cancer	0.000229	0.00142	CcSEcCtD
Canagliflozin—Shock—Epirubicin—testicular cancer	0.000227	0.00141	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—testicular cancer	0.000226	0.00141	CcSEcCtD
Canagliflozin—Nervous system disorder—Epirubicin—testicular cancer	0.000226	0.00141	CcSEcCtD
Canagliflozin—Skin disorder—Epirubicin—testicular cancer	0.000224	0.00139	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000221	0.00137	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—testicular cancer	0.000217	0.00135	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—HPGDS—testicular cancer	0.000215	0.00588	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—HPGDS—testicular cancer	0.000215	0.00588	CbGpPWpGaD
Canagliflozin—Hypotension—Epirubicin—testicular cancer	0.000215	0.00134	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000213	0.00132	CcSEcCtD
Canagliflozin—Fatigue—Methotrexate—testicular cancer	0.000212	0.00132	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—testicular cancer	0.000212	0.00132	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—testicular cancer	0.00021	0.00131	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—testicular cancer	0.000209	0.0013	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—testicular cancer	0.000207	0.00129	CcSEcCtD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	0.000207	0.00565	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Methotrexate—testicular cancer	0.000201	0.00125	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—testicular cancer	0.000199	0.00124	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000199	0.00124	CcSEcCtD
Canagliflozin—Fatigue—Epirubicin—testicular cancer	0.000199	0.00124	CcSEcCtD
Canagliflozin—Constipation—Epirubicin—testicular cancer	0.000197	0.00123	CcSEcCtD
Canagliflozin—Urticaria—Methotrexate—testicular cancer	0.000196	0.00122	CcSEcCtD
Canagliflozin—Abdominal pain—Methotrexate—testicular cancer	0.000195	0.00121	CcSEcCtD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00019	0.00518	CbGpPWpGaD
Canagliflozin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000188	0.00117	CcSEcCtD
Canagliflozin—SLC5A2—Disease—H2AFZ—testicular cancer	0.000188	0.00514	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—H2AFZ—testicular cancer	0.000188	0.00514	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000184	0.00115	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—testicular cancer	0.000184	0.00114	CcSEcCtD
Canagliflozin—Urticaria—Epirubicin—testicular cancer	0.000183	0.00114	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—testicular cancer	0.000182	0.00113	CcSEcCtD
Canagliflozin—Abdominal pain—Epirubicin—testicular cancer	0.000182	0.00113	CcSEcCtD
Canagliflozin—Hypersensitivity—Methotrexate—testicular cancer	0.000181	0.00113	CcSEcCtD
Canagliflozin—Asthenia—Methotrexate—testicular cancer	0.000177	0.0011	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000174	0.00108	CcSEcCtD
Canagliflozin—Pruritus—Methotrexate—testicular cancer	0.000174	0.00108	CcSEcCtD
Canagliflozin—SLC5A2—Disease—KITLG—testicular cancer	0.000173	0.00472	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KITLG—testicular cancer	0.000173	0.00472	CbGpPWpGaD
Canagliflozin—Hypersensitivity—Epirubicin—testicular cancer	0.00017	0.00106	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—testicular cancer	0.000169	0.00105	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—testicular cancer	0.000169	0.00105	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—HPGDS—testicular cancer	0.000166	0.00454	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000166	0.00454	CbGpPWpGaD
Canagliflozin—Asthenia—Epirubicin—testicular cancer	0.000165	0.00103	CcSEcCtD
Canagliflozin—Pruritus—Epirubicin—testicular cancer	0.000163	0.00101	CcSEcCtD
Canagliflozin—Dizziness—Methotrexate—testicular cancer	0.000163	0.00101	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—testicular cancer	0.000157	0.000977	CcSEcCtD
Canagliflozin—SLC5A1—Metabolism—STK11—testicular cancer	0.000157	0.00428	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—STK11—testicular cancer	0.000157	0.00428	CbGpPWpGaD
Canagliflozin—Rash—Methotrexate—testicular cancer	0.000155	0.000966	CcSEcCtD
Canagliflozin—Dermatitis—Methotrexate—testicular cancer	0.000155	0.000965	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—testicular cancer	0.000153	0.000952	CcSEcCtD
Canagliflozin—Dizziness—Epirubicin—testicular cancer	0.000152	0.000948	CcSEcCtD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000152	0.00415	CbGpPWpGaD
Canagliflozin—Pruritus—Doxorubicin—testicular cancer	0.000151	0.000939	CcSEcCtD
Canagliflozin—Nausea—Methotrexate—testicular cancer	0.000146	0.00091	CcSEcCtD
Canagliflozin—Rash—Epirubicin—testicular cancer	0.000145	0.000904	CcSEcCtD
Canagliflozin—Dermatitis—Epirubicin—testicular cancer	0.000145	0.000903	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—testicular cancer	0.000141	0.000877	CcSEcCtD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000138	0.00378	CbGpPWpGaD
Canagliflozin—Nausea—Epirubicin—testicular cancer	0.000137	0.000852	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—testicular cancer	0.000134	0.000837	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—testicular cancer	0.000134	0.000836	CcSEcCtD
Canagliflozin—SLC5A1—Disease—FGFR3—testicular cancer	0.000129	0.00351	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—FGFR3—testicular cancer	0.000129	0.00351	CbGpPWpGaD
Canagliflozin—Nausea—Doxorubicin—testicular cancer	0.000127	0.000788	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—STK11—testicular cancer	0.000121	0.0033	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KIT—testicular cancer	0.000118	0.00322	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KIT—testicular cancer	0.000118	0.00322	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00011	0.00301	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000102	0.00278	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.24e-05	0.00198	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—HPGDS—testicular cancer	6.16e-05	0.00168	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—STK11—testicular cancer	4.47e-05	0.00122	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—HPGDS—testicular cancer	3.22e-05	0.00088	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—HPGDS—testicular cancer	2.82e-05	0.000771	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—STK11—testicular cancer	2.34e-05	0.00064	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—STK11—testicular cancer	2.05e-05	0.000561	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—HPGDS—testicular cancer	1.74e-05	0.000475	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—STK11—testicular cancer	1.26e-05	0.000345	CbGpPWpGaD
